🇺🇸 FDA
Patent

US 12031157

Closed process for expansion and gene editing of tumor infiltrating lymphocytes and uses of same in immunotherapy

granted A61KA61K2039/5158A61K35/17

Quick answer

US patent 12031157 (Closed process for expansion and gene editing of tumor infiltrating lymphocytes and uses of same in immunotherapy) held by Iovance Biotherapeutics, Inc. expires Mon Jul 04 2044 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Iovance Biotherapeutics, Inc.
Grant date
Tue Jul 09 2024 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jul 04 2044 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
30
CPC classes
A61K, A61K2039/5158, A61K35/17, A61K39/0011